Business Wire10d
Tris Pharma Announces Positive Results from ALLEVIATE-2 Phase 3 Pivotal Trial for Cebranopadol, an Investigational First-in-Class Oral Dual-NMR Agonist, for the Trea…
Tris Pharma, Inc. (Tris), a commercial-stage biopharmaceutical company, today announced positive topline results from its ...
TransMedics Reports Q4 revenue $121.62M, consensus $109.49M.
Reports Q4 revenue $121.62M, consensus $109.49M. “We are proud of our 2024 results as we delivered 83% year over year revenue growth while ...